L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats

Hypertension Research

Volumn 34, Issue 4, 2011, Pages 521-529

  Toba, Hiroe ^a   Yoshida, Mamiko ^a   Tojo, Chisato ^a   Nakano, Arisa ^a   Oshima, Yuko ^a   Kojima, Yushi ^a   Noda, Kazuki ^a   Wang, Jiahong ^a   Kobara, Miyuki ^a   Nakata, Tetsuo ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

aldosterone; angiotensin converting enzyme; calcium channel blockers; kidney

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; AMLODIPINE; ANGIOTENSIN; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CILNIDIPINE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CREATININE; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; NORADRENALIN; PODOCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; SODIUM CHLORIDE; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; MALE; NONHUMAN; NORADRENALIN URINE LEVEL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYMPATHETIC NERVE; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; WESTERN BLOTTING;

AMLODIPINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; COLLAGEN; DESOXYCORTICOSTERONE; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; HYPERTENSION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MEMBRANE PROTEINS; PROTEINURIA; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 79953723169     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.279     Document Type: Article

References (46)

1. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18. (Pubitemid 26012498)
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, Van Zwieten P, Waeber B, Williams B. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
4. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
5. Kimura G. Glomerular function reserve and sodium sensitivity. Clin Exp Nephrol 2005; 9: 102-113. (Pubitemid 40875098)
6. Konishi Y, Imanishi M, Okamura M, Yoshioka K, Okumura M, Okada N, Tanaka S, Fujii S, Kimura G. Relationship of renal histological damage to glomerular hypertension in patients with immunoglobulin A nephropathy. J Hypertens 2000; 18: 103-109. (Pubitemid 30093715)
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
8. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431. (Pubitemid 35340538)
9. Anderson S, Rennke HG, Brenner BM. Nifedipine vs. fosinopril in uninephrectomized diabetic rats. Kidney Int 1992; 41: 891-897.
10. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808-814. (Pubitemid 23105213)
11. Kimura K, Tojo A, Hirata Y, Hayakawa H, Goto A, Omata M. Effects of a calcium antagonist and an angiotensin II receptor antagonist on rat renal arterioles. Blood Press Suppl 1994; 5: 71-74. (Pubitemid 24380443)
12. Boero R, Pignataro A, Ferro M, Quarello F. Sympathetic nervous system and chronic renal failure. Clin Exp Hypertens 2001; 23: 69-75. (Pubitemid 32183257)
13. Fujii T, Kurata H, Takaoka M, Muraoka T, Fujisawa Y, Shokoji T, Nishiyama A, Abe Y, Matsumura Y. The role of renal sympathetic nervous system in the pathogenesis of ischemic acute renal failure. Eur J Pharmacol 2003; 481: 241-248. (Pubitemid 37464976)
14. Luippold G, Beilharz M, Muhlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 2004; 19: 342-347. (Pubitemid 38195982)
15. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359. (Pubitemid 34260428)
16. 2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
17. 2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 1988; 239: 57-61. (Pubitemid 18029496)
18. Hosono M, Fujii S, Hiruma T, Watanabe K, Hayashi Y, Ohnishi H, Takata Y, Kato H. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn J Pharmacol 1995; 69: 127-134.
19. Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, Miho N. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 1999; 33: 1447-1452. (Pubitemid 29282669)
20. Tominaga M, Ohya Y, Tsukashima A, Kobayashi K, Takata Y, Koga T, Yamashita Y, Fujishima Y, Abe I, Fujishima M. Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine. Cardiovasc Drugs Ther 1997; 11: 43-48. (Pubitemid 27153558)
21. Yoshimoto R, Hashiguchi Y, Dohmoto H, Hosono M, Iida H, Fujiyoshi T, Ikeda K, Hayashi Y. Effects of a new dihydropyridine derivative FRC-8653, on blood pressure in conscious spontaneously hypertensive rats. J Pharmacobiodyn 1992; 15: 25-32.
22. Hansen PB, Jensen BL, Andreasen D, Skott O. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630-638. (Pubitemid 32924218)
23. Fujisawa T, Ikegami H, Noso S, Hiromine Y, Kawabata Y, Nishino M, Asano K, Ogihara T. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy. J Diabetes Compl 2007; 21: 252-257. (Pubitemid 47007748)
24. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27: 379-385. (Pubitemid 38996928)
25. Morimoto S, Yano Y, Maki K, Iwasaka T. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J Hypertens 2007; 25: 2178-2183. (Pubitemid 47476317)
26. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K. Antiproteinuric effect of the calcium channel blocker cilnidipine added to reninangiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-1549. (Pubitemid 350199443)
27. Koepke JP, Jones S, DiBona GF. Renal nerve activity and renal function during environmental stress in DOCA-NaCl rats. Am J Physiol 1986; 251: R289-R294.
28. Shimamura T. 11-Deoxycorticosterone-induced hypertension, glomerulosclerosis and renal arterial and arteriolar lesions. Jpn J Exp Med 1988; 58: 225-228. (Pubitemid 18268962)
29. Manning Jr RD, Meng S, Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 2003; 179: 243-250. (Pubitemid 37464109)
30. Hirooka Y, Kimura Y, Nozoe M, Sagara Y, Ito K, Sunagawa K. Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats. Hypertens Res 2006; 29: 49-56.
31. Yamazaki H, Yoshimura M, Kambara S, Lee LC, Fukuyama M, Sasaki S, Takahashi H, Takeda K, Ijichi H. Enhanced renal sympathetic nerve activity in response to salt loading in rats. Jpn Circ J 1986; 50: 442-448. (Pubitemid 16010066)
32. Toba H, Sawai N, Morishita M, Murata S, Yoshida M, Nakashima K, Morita Y, Kobara M, Nakata T. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009; 612: 106-114.
33. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101: p1-13.
34. Agarwal R, Campbell RC, Warnock DG. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol 2004; 24: 101-114. (Pubitemid 38387851)
35. Nistala R, Whaley-Connell A, Sowers JR. Redox control of renal function and hypertension. Antioxid Redox Signal 2008; 10: 2047-2089.
36. Hishikawa K, Takase O, Idei M, Fujita T. Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int 2009; 76: 230-231.
37. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75-197. (Pubitemid 27069290)
38. Steinhausen M, Ballantyne D, Fretschner M, Hoffend J, Parekh N. Different responses of cortical and juxtamedullary arterioles to norepinephrine and angiotensin II. Kidney Int Suppl 1990; 30: S55-S59. (Pubitemid 20376251)
39. Konno Y, Kimura K. Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int Heart J 2008; 49: 723-732.
40. Niijima A, Okui T, Matsumura Y, Yamano T, Tsuruoka N, Kiso Y, Nagai K. Effects of L-carnosine on renal sympathetic nerve activity and DOCA-salt hypertension in rats. Auton Neurosci 2002; 97: 99-102. (Pubitemid 34603133)
41. Motoyama T, Sano H, Miki T, Suzuki H, Kawaguchi K, Furuta Y, Fukuzaki H. The role of chloride in the sympathetic nervous system in DOCA-salt hypertension. Am J Hypertens 1988; 1: 287-290.
42. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, Nitta K. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin- aldosterone system in SHR/Izm. Am J Nephrol 2009; 30: 155-161.
43. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697. (Pubitemid 28397387)
44. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364. (Pubitemid 46143013)
45. Konda T, Enomoto A, Takahara A, Yamamoto H. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 2006; 29: 933-937.
46. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51: 742-748. (Pubitemid 351301529)